Eric M. Bonnem - Concepedia

Author

Eric M. Bonnem

University of Washington

Also Known As

E Bonnem, E Littler, E M Bonnem, E. Bonnem, E. M. Bonnem, ERIC BONNEM, Eric Bonnem, Eric M. Bonnem, J Rafecas

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

University of Washington The Christie Hospital Georgetown University Georgetown University Medical Center City Of Hope National Medical Center

About

Eric M. Bonnem is an author at University of Washington specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	15	760
2	Health Sciences	5	5	156
3	Clinical Immunology	1	1	67
4	Critical Care Medicine	1	1	15
5	Emergency Medicine	1	1	15

Eric M. Bonnem

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects. John A. Thompson, D J Lee, Pamela G. Kidd, Journal of Clinical Oncology Hematological MalignancyMyelodysplastic SyndromeBone Marrow FailureGranulocyteHematological Effects	1989	177
Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions – a phase I dose-toxicity study J.H. Scarffe, Robert D. Austin, Eric M. Bonnem, British Journal of Cancer InflammationDaily Short InfusionsGranulocyteDose-toxicity StudyImmunology	1989	85
Randomized Study of the Duration of Treatment With Interferon Alfa-2B in Patients With Hairy Cell Leukemia Harvey M. Golomb, Mark J. Ratain, A Fefer, JNCI Journal of the National Cancer Institute	1988	77
High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma B Barlogie, S Jagannath, DO Dixon, Blood	1990	77
Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration. Graham J. Lieschke, Dermot Maher, M O'Connor, PubMed ImmunologyBlood CellPathologyImmunotherapyInflammation	1990	68
High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma Bart Barlogie, Sundar Jagannath, DO Dixon, Blood	1990	68
Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections – a phase I dose toxicity trial J.H. Scarffe, A K Ghosh, C M Heyworth, British Journal of Cancer Clinical ImmunologyInflammationCytokineSubcutaneous InjectionsImmunotoxicology	1992	67
Reversal of Heparin Anticoagulation by Recombinant Platelet Factor 4 in Humans Gregory Dehmer, Melrose Fisher, David A. Tate, Circulation	1995	62
Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon-alfa2b. Harvey M. Golomb, A Fefer, David W. Golde, PubMed Hematological MalignancyMedicineHematologyPathologyHairy Cell Leukemia	1988	58
A prospective randomized trial of alpha 2B-interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma. Kenneth A. Foon, James H. Doroshow, Eric M. Bonnem, PubMed UrologyRenal FunctionGenitourinary CancerKidney ResearchMedicine	1988	49

Page 1